Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial – Authors’ reply

By afschroeder • August 17, 2025

Kudo M, Ren Z, Finn RS, Llovet JM; LEAP-012 investigators. Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply. Lancet. 2025 Aug 16;406(10504):694. doi: 10.1016/S0140-6736(25)01441-2. PMID: 40818849.

Tags: Hematology/Oncology, Publications

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis

Pontolillo L, Davis AA, Gerratana L, Medford AJ, Wang J, Nicolo' E, Clifton K, Velimirovic M, Warrior S, Podany E, Andreopoulou E, Serafini MS, Munoz-Arcos[...]

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J,[...]

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]